公开(公告)号：WO2023277730A1

公开(公告)日：2023-01-05

申请号：PCT/RU2022/000207

申请日：2022-06-30

Applicant: МУСАХАНОВА, Ойгуль Мирзаюсуфовна

Inventor： АЗИМОВА, Шахноз Садыковна ,  СААТОВ, Талат Саатович ,  ЗАЙНУТДИНОВ, Баходир Равилович ,  АШИРОВ, Ойбек Норбой ,  САСМАКОВ, Собирджан Анарматович ,  ЛЫСОВА, Елена ,  МАХНЕВ, Артем Александрович ,  УМАРОВА, Мукаддас Рустамовна ,  ХАМИДОВА, Умида Бахриддин кизи ,  ПИЯКИНА, Галина Александровна ,  АБДУРАХМАНОВ, Джалолиддин Мирджамилович ,  ХАСАНОВ, Шухрат Шавкатович ,  ЭШБОЕВ, Фарход Бакир

IPC: A61K9/127 ,  A61K31/167 ,  A61K38/43 ,  A61P31/14

Abstract: Изобретение относится к медицине, фармацевтике и биотехнологии. Представлена новая фармацевтическая композиция, обладающая противовирусным эффектом в отношении коронавируса SARS-CoV-2 и родственных вирусов, таких как SARS, MERS и др., геном которых представлен РНК, а вирионы снабжены липидной оболочкой. Комбинированное лекарственное средство для профилактики заражения (лечения) SARS-CoV-2 представляет собой (i) - липосому с эффективным количеством фермента РНКазы, или (ii) - липосому с эффективным количеством фермента РНКазы и эффективным количеством препарата никлозамида, вспомогательное средство - растворитель, разрешенный к применению в фармацевтике. Изобретение обеспечивает разрушение генетического материала - РНК коронавирусов, что дает возможность профилактики от РНК-содержащих вирусов, в том числе SARS-CoV-2, попадающих в организм человека через верхние дыхательные пути.

公开(公告)号：WO2022264058A1

公开(公告)日：2022-12-22

申请号：PCT/IB2022/055541

申请日：2022-06-15

Applicant: NEILOS S.R.L.

Inventor： DI MAIO, Umberto

IPC: A61K36/22 ,  A61K36/537 ,  A61K38/43 ,  A61P29/00 ,  A61K2300/00 ,  A61K38/4873

Abstract: A composition containing a combination of an extract of Mangifera indica, bromelain and an extract of Salvia officinalis is described, which is useful for the prevention and/or treatment of inflammatory diseases and in particular osteoarticular, urogenital, dental, and gynecological inflammatory diseases in both humans and animals. The composition is particularly effective due to the synergistic action of its components.

公开(公告)号：WO2022226303A1

公开(公告)日：2022-10-27

申请号：PCT/US2022/025945

申请日：2022-04-22

Applicant: PRECISION BIOSCIENCES, INC. ,  UNIVERSITY OF MIAMI

Inventor： MORAES, Carlos T. ,  SMITH, James Jefferson ,  JANTZ, Derek ,  TOMBERLIN, Ginger H. ,  MORRIS, John ,  SHOOP, Wendy

IPC: C12N9/22 ,  A61K38/43

Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA). The disclosure further relates to the use of such recombinant meganucleases in combination with mitochondrial transit peptides in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been modified or edited.

公开(公告)号：WO2022204574A1

公开(公告)日：2022-09-29

申请号：PCT/US2022/022050

申请日：2022-03-25

Applicant: BEAM THERAPEUTICS INC.

Inventor： GAUDELLI, Nicole ,  LEE, Seung-Joo ,  FELICIANO, Patricia, Rosa ,  LAM, Dieter Ka Yeung

IPC: A61K38/43 ,  C12N15/09 ,  C12N15/52

Abstract: The invention provides adenosine deaminase variants that are capable of deaminating adenine and/or cytosine in a target polynucleotide (e.g., DNA). The disclosure also provides multi-molecular complexes, fusion proteins, base editors, and base editor systems comprising the adenosine deaminase variants with adenine and cytosine deaminase activity and/or cytosine deaminase specificity, and methods of use thereof.

公开(公告)号：WO2022195000A1

公开(公告)日：2022-09-22

申请号：PCT/EP2022/056952

申请日：2022-03-17

Applicant: INOFEA AG ,  NBE-THERAPEUTICS AG

Inventor： SHAHGALDIAN, Patrick ,  BRIAND, Manon ,  CORVINI, Philippe F.-X. ,  CORRERO, Maria Rita ,  DUDAL, Yves ,  GRAWUNDER, Ulf ,  GEBLEUX, Rémy ,  BEERLI, Roger R.

IPC: A61K38/43 ,  B82Y5/00 ,  C12N9/96 ,  C12N11/04 ,  C12N11/14 ,  G01N33/549 ,  G01N33/547 ,  C07K1/107 ,  B82Y15/00 ,  C12N9/64

Abstract: The present invention relates to a composition comprising a solid carrier, a capture moiety, afunctional protein, a first linker connecting the capture moiety to the solid carrier, a second linker connecting the functional protein to the capture moiety, a first protective layer fully embedding the solid carrier, fully or partially embedding the first linker and not or partially embedding the capture moiety, a second protective layer fully or partially embedding the capture moiety, fully embedding the second linker and fully or partially embedding the functional protein.

公开(公告)号：WO2022175262A1

公开(公告)日：2022-08-25

申请号：PCT/EP2022/053673

申请日：2022-02-15

Applicant: DSM IP ASSETS B.V. ,  NOVOZYMES A/S

Inventor： CLAYPOOL, Joshua ,  FREEMAN, Kevin ,  SCHYNS, Ghislain

IPC: A61K38/43 ,  A23K20/189 ,  A23K50/30 ,  C12N9/36 ,  A23K20/111 ,  A23K20/163 ,  A23K50/70 ,  A61P1/12 ,  G01N33/569 ,  A61P31/04

Abstract: The present disclosure relates to methods of modulating level of E. coli present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level of LEE and non-LEE pathogenic genes in the microbiome of the host animal. The present disclosure further relates to methods of modulating the virulence of pathogenic E. coli in the gastrointestinal tract of an animal by reducing the population of B. thetaiotaomicron in the gut microbiome of the animal.

公开(公告)号：WO2022169634A1

公开(公告)日：2022-08-11

申请号：PCT/US2022/013676

申请日：2022-01-25

Applicant: UNM RAINFOREST INNOVATIONS

Inventor： XUE, Xiang

IPC: A61K31/00 ,  A61K45/06 ,  A61K38/43 ,  A61N5/00 ,  A61P35/00 ,  A61N2005/1098

Abstract: The present invention is directed to the unexpected discovery that iron chelators and anticancer agents, such as checkpoint kinase 1 (CHK1) inhibitors, ATR inhibitors and DNA damaging agents, and/or radiotherapy when combined in effective amounts, exhibit a synergistic effect in the inhibition and treatment of cancer. Accordingly, the present invention is directed to methods for the treatment of cancer which combine effective amounts of an iron chelator and a Chkl inhibitor, a ATR inhibitor, a DNA damaging agent and/or radiotherapy. Optionally, an additional anticancer agent may be used in the treatment of cancer. In alternative embodiments, the present invention is directed to pharmaceutical compositions which are used in the treatment of cancer and comprise an effective amount of at least one iron chelator, and at least one or more of a Chkl inhibitor, ATR inhibitor and/or DNA damaging agent, optionally in combination with one of more additional anticancer agent as described herein in combination with a pharmaceutically acceptable carrier, additive or excipient.

公开(公告)号：WO2022149125A1

公开(公告)日：2022-07-14

申请号：PCT/IL2022/050003

申请日：2022-01-02

Applicant: RAMOT AT TEL AVIV UNIVERSITY LTD.

Inventor： BARUCH LESHEM, Avigail-Elah ,  LAMPEL, Ayala ,  MASSARANO, Tlalit

IPC: A61Q1/02 ,  A61K8/02 ,  A61K8/72 ,  A61Q17/04 ,  A61Q19/04 ,  A61K31/721 ,  A61K31/25 ,  A61K31/135 ,  A61K31/133 ,  A61K31/404 ,  A61K38/43

Abstract: The invention relates to a composition comprising a polymer - based droplet, wherein the polymer - based droplet comprises one or more of melanin, a tyrosine substrate with a cleavable protecting group on the side chain, tyrosine, tyrosinase and any combination thereof. The composition further relates to a method of synthesizing melanin comprising the steps of: obtaining a polymer - based droplet containing a tyrosine substrate with a cleavable protecting group on the side chain (protected tyrosine) or a polymer - based droplet containing tyrosine (unprotected); wherein the tyrosine is oxidized by tyrosinase and polymerizes so as to obtain melanin.

公开(公告)号：WO2022066832A1

公开(公告)日：2022-03-31

申请号：PCT/US2021/051641

申请日：2021-09-23

Applicant: MERCK SHARP & DOHME CORP. ,  KRISHNAMACHARI, Yogita ,  MITTAL, Sachin ,  SANGANI, Sahil, S. ,  FORREST, William, P., Jr. ,  SU, Yongchao ,  ZHAO, Xi

Inventor： KRISHNAMACHARI, Yogita ,  MITTAL, Sachin ,  SANGANI, Sahil, S. ,  FORREST, William, P., Jr. ,  SU, Yongchao ,  ZHAO, Xi

IPC: C07K16/28 ,  A61K38/43 ,  A61K39/395

Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.

公开(公告)号：WO2022060151A1

公开(公告)日：2022-03-24

申请号：PCT/KR2021/012763

申请日：2021-09-17

Applicant: 한양대학교 산학협력단

Inventor： 류성언 ,  장혜현 ,  김명빈 ,  박성호

IPC: C12N9/16 ,  A61K38/43 ,  A61P35/00 ,  A61K38/00

Abstract: 본 발명은 PTPsigma(Protein Tyrosine Phosphatase sigma) 유래의 단백질 및 면역글로불린(Immunoglobulin, Ig) 유래의 Fc 도메인을 포함하여, PTPsigma의 세포외도메인과 리간드의 상호작용을 차단함으로써 PTPsigma의 신호전달을 억제할 수 있는 PTPsigma-Fc 융합단백질에 관한 것이다. 본 발명의 PTPsigma-Fc 융합단백질은 PTPsigma 매개의 신호전달을 저해하여 혈액줄기세포 생장을 촉진할 수 있고, PTPsigma 매개성 질환의 예방 또는 치료에 이용될 수 있다. 본 발명에 따른 PTPsigma-Fc 융합단백질은 단백질 간의 상호작용을 이용하여 PTPsigma의 신호전달을 조절하므로 종래 PTP의 활성부위를 타겟으로 하는 저해제들의 문제를 극복할 수 있다. 또한, 융합단백질에 돌연변이를 도입하여 수용액 용해도를 향상시킴으로써 인체 및 동물 치료 시 고용량으로 처리할 수 있다.